Schizophrenia Spectrum and Other Psychotic Disorders

A 19-year-old with his first psychotic episode needs an antipsychotic started this week. Head-to-head trials have never shown one second-generation agent reliably outperforming another — so what is the decision actually resting on?

A year symptom-free after one clean psychotic episode, a patient wants to stop her medication. Guidelines themselves don't agree on whether that's a reasonable next step or a real relapse gamble.

A newly diagnosed patient with real insight into his own illness still has a family history of stopping antipsychotics against medical advice. Does his LAI conversation start now, or only after he actually misses doses?

A patient has already failed two adequate antipsychotic trials — the guideline threshold for clozapine. The medication most likely to help her is also the one everyone in the room is most reluctant to start.

Clozapine at an adequate trial and a confirmed therapeutic level still leaves residual voices she cannot ignore. Every augmentation option on the table rests on genuinely thin, competing evidence.

The one drug that ever controlled his psychosis nearly cost him his life a different way. With no other effective option ever found, rechallenge is a real question, not a reckless one.

A patient ready to switch to a long-acting injectable has real insurance limits standing between him and the formulation with the best side-effect profile. The choice is genuinely constrained, not just clinical.

Clozapine isn't an option for him, and the next-most-common real-world response is combining two antipsychotics — a widespread practice with a genuinely weak trial base behind it.

Olanzapine works better than anything either of these two patients has tried — and is quietly reshaping both of their metabolic health while it does. The same drug, the same tension, two very different answers.

Real weight gain on olanzapine has a well-established, cheaper answer and a newer, more effective one that his insurance won't cover without a fight. The tradeoff is genuinely between evidence and access.

New involuntary facial movements after years of stable antipsychotic treatment used to mean switching and hoping. A newer class of drug designed for exactly this now makes that traditional first response genuinely optional.

Two pregnant women with schizophrenia, one many years into stable remission and one newly diagnosed and still unstable, face the same relapse-versus-exposure tradeoff with very different real stakes behind it.

A black-box warning links antipsychotics to increased mortality in dementia patients — and her psychotic agitation has already made her a danger to herself at home. The overuse-versus-necessity argument here is real on both sides.

He clearly meets the clinical threshold for clozapine, but ongoing cannabis and intermittent stimulant use complicate both monitoring reliability and interaction risk. Excluding him isn't obviously right, and neither is proceeding as if the use isn't there.

A young woman in catatonic stupor is beginning to show autonomic instability. The standard benzodiazepine challenge is still first-line, but exactly how long to wait for it to work before escalating to ECT is a real, live disagreement.

His catatonia responded well to lorazepam, but the psychotic disorder underneath it is still fully active. Restarting an antipsychotic risks the exact symptom that just resolved, in a genuinely underrecognized way.

Antipsychotics have only modest evidence in delusional disorder, and he doesn't believe anything is wrong with him to begin with. Pushing medication and focusing on function instead are both genuinely defensible paths.

Visual hallucinations are eroding his independence, but nearly every antipsychotic that could help also risks worsening the Parkinson's motor symptoms already limiting him. The dopamine-blocking risk genuinely changes the usual calculus.

A genuinely new antipsychotic mechanism, free of direct D2 blockade, is now available — but with only a couple of years of real-world experience behind a decades-old field, how it should actually be positioned is a live, unsettled question.

Her psychotic symptoms are well controlled, but persistent cognitive difficulty is what's actually keeping her from returning to work. Nothing is FDA-approved for this, and the off-label options all rest on weak evidence.

His voices are gone, but the flat affect and social withdrawal that came with his illness never left. A newer agent claims real benefit for exactly this — but how much of that claim actually holds up is genuinely contested.

Two long-stable patients both ask about lowering their antipsychotic dose. The real research question — who can actually tolerate this — plays out in opposite directions once their individual illness histories are weighed honestly.

Her psychotic symptoms are controlled, but the depressive episodes that define her diagnosis keep recurring. Whether that calls for a genuinely separate antidepressant or is better handled within the antipsychotic alone is a real, unsettled question.

He needs rapid pharmacologic control for acute agitation, and his baseline ECG already shows a borderline-prolonged QTc before any antipsychotic is even given. The usual first-line options carry real, differentiated cardiac risk here.

A severely agitated patient needs medication now, and the team disagrees on the actual first-line choice — an antipsychotic alone, a benzodiazepine alone, or both together — a genuinely common, genuinely disputed decision made under real time pressure.

He's smoked two packs a day for years, and hospital admission just stopped that overnight. His clozapine dose was calibrated for a smoker's faster drug clearance — and that clearance is now changing fast, underrecognized until levels start climbing.